Insider Shareholders with Direct Ownership of Intra Cellular Therapies, Inc. (ITCI)
This section provides a comprehensive overview of the insiders with direct ownership of Intra Cellular Therapies, Inc. (ITCI). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Intra-Cellular Therapies, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
|
Sharon Mates
Chairman and CEO |
1,192,865 | 1,320,314 | 1,085,943 $138 Million | 71 |
Jan 31, 2025
Reduced 1.38%
|
|
Christopher D Alafi
Director |
1,572 | 0 | 346,795 $44.1 Million | 3 |
Mar 31, 2021
Added 0.13%
|
| 75,605 | 4,462 | 131,512 $16.7 Million | 24 |
Dec 31, 2024
Added 0.16%
|
|
| 66,280 | 89,707 | 41,229 $5.24 Million | 10 |
Jun 23, 2024
Added 3.66%
|
|
|
Mark Neumann
EVP, Chief Commercial Officer |
380,450 | 365,926 | 35,988 $4.57 Million | 42 |
Jan 31, 2025
Reduced 11.61%
|
|
Suresh K. Durgam
EVP, Chief Medical Officer |
187,946 | 170,615 | 26,090 $3.32 Million | 33 |
Jan 31, 2025
Reduced 15.35%
|
| 83,773 | 80,000 | 11,340 $1.44 Million | 25 |
Jun 28, 2024
Added 0.73%
|
|
|
Michael Halstead
President |
623,425 | 622,524 | 5,326 $677,041 | 44 |
Jan 31, 2025
Reduced 51.66%
|
| 1,567 | 0 | 1,567 $199,197 | 1 |
Jun 23, 2024
Added 50.0%
|
|
|
Lawrence J. Hineline
SVP of Finance, CFO |
566,678 | 574,712 | 0 $0 | 40 |
Mar 11, 2024
Reduced 100.0%
|